Maureen F Paravecchia

Maureen F. Paravecchia serves as a procurement specialist focused on high-compliance, science-driven acquisitions within the federal government, primarily supporting the development and procurement of advanced pharmaceutical and biological products. Her role centers on managing complex contracting actions under the Federal Acquisition Regulation, ensuring alignment with public health objectives and regulatory standards. She typically handles competitive and non-competitive procurements for mission-critical medical manufacturing capabilities, with an emphasis on ensuring supply chain resilience and quality assurance in regulated environments. Her work directly supports national health security initiatives through the acquisition of active pharmaceutical ingredients, biologics, and specialized formulation systems. Her contractor relationships are predominantly with manufacturers possessing cGMP certification and FDA-regulated production facilities, particularly those with expertise in sterile compounding, lyophilization, and biologics processing. While no single vendor dominates her portfolio, she consistently engages with mid-to-large-scale contract development and manufacturing organizations (CDMOs) capable of meeting stringent quality and validation requirements. Her procurement approach emphasizes technical capability assessments, pre-award site evaluations, and performance-based contract structures to ensure consistent product integrity and regulatory compliance. Paravecchia’s contracting patterns reflect a strong preference for open competition, with 91.7% of her awards issued without set-aside restrictions. The remaining 8.3% are awarded under Total Small Business Set-Asides per FAR 19.5, demonstrating a measured but deliberate commitment to small business participation—particularly among firms with validated manufacturing capabilities in pharmaceutical and biological production. She does not routinely utilize 8(a), HUBZone, or SDVOSB set-asides, prioritizing technical readiness and capacity over socioeconomic designations. Her primary procurement focus lies in NAICS 325412 (Pharmaceutical Preparation Manufacturing) and 325414 (Biological Product Manufacturing), reflecting deep expertise in drug formulation, biologics production, and aseptic processing. She also occasionally procures specialized foam-based delivery systems under NAICS 326150. Her technical domain expertise spans GMP compliance, cold chain logistics, and product stability testing, positioning her as a key contact for acquisitions requiring advanced pharmaceutical manufacturing capabilities.